West Pharmaceutical Services Inc (WST)

West Appoints Michel Lagarde to be President and Chief Executive OfficerJune 1, 2026 4:30 PM
PR Newswire (US) Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026. He succeeds Eric M. Green, who will retire from his roles as President, CEO and Board Chair on that date. The Company also announced as part of the CEO transition that the Board has elected Lead Independent Director Robert F. Friel to become Board Chair effective August 31, 2026. "Michel is an accomplished leader whose experience demonstrates the precise blend of visionary insight, customer-centric mindset, and exceptional leadership skills the Board sought throughout the search process. Throughout his career, Michel has demonstrated an unwavering commitment to customers, an ability to build high-performing teams and an impressive track record of long-term value creation, which makes him exceptionally well suited to lead West at this time," said Robert F. Friel."I'm honored to lead West into its next chapter of growth and to build on the company's trusted reputation and enduring mission of improving patient health," commented Michel Lagarde, incoming President and CEO, West. "The life sciences industry is at a pivotal point. As innovation accelerates and AI reshapes how therapies are developed, the demand for reliable, high-quality delivery of injectable medicines has never been greater—and that is exactly where West excels. I look forward to working alongside this talented team to help our customers deliver innovative therapies to patients around the world—faster than ever before. This mission is what connects all of our stakeholders—colleagues, customers, and shareholders alike—because nothing creates more lasting value than improving patients' lives."About Michel Lagarde
Mr. Lagarde brings extensive global experience helping pharmaceutical and biotech companies succeed by delivering critical products and services. Most recently, he served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, Inc., with responsibility for the majority of the company's businesses. He joined Thermo Fisher in 2017 as Senior Vice President and President, Pharma Services, through its acquisition of Patheon N.V.Before Thermo Fisher, Mr. Lagarde was President and Chief Operating Officer at Patheon N.V., a pharma services company, from 2016 to 2017, and Managing Director at JLL Partners, a private equity firm focused on health care services, from 2008 to 2016. Earlier in his career, he spent 12 years at Philips, a global leader in health technology, in a range of finance roles across several international markets.In 2023, Mr. Lagarde joined the Board of Directors of Vertex Pharmaceuticals, where he serves as Chair of the Audit and Finance Committee. He holds a Bachelor of Business Administration (BBA) from European University in Antwerp, Belgium, and an executive master's degree in finance and control from Maastricht University in the Netherlands.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites, including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of?West Pharmaceutical Services, Inc.?or its subsidiaries, in?the United States?and other jurisdictions, unless otherwise noted.   View original content to download multimedia:https://www.prnewswire.com/news-releases/west-appoints-michel-lagarde-to-be-president-and-chief-executive-officer-302787533.htmlSOURCE West Pharmaceutical Services, Inc. Original: West Appoints Michel Lagarde to be President and Chief Executive Officer

West to Participate in Upcoming Investor ConferencesApril 28, 2026 6:00 AM
PR Newswire (US)

EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences:







Bank of America Global Healthcare Conference on Tuesday, May 12, 2026 at 2:20 p.m. PDT in Las Vegas, NVWilliam Blair Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:00 p.m. CDT in Chicago, ILThe live webcasts for these events can be accessed in the Investors section of the Company's website. A replay of each webcast will also be available on the Company's website for approximately 90 days after each respective event. About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of?West Pharmaceutical Services, Inc.?or its subsidiaries, in?the United States?and other jurisdictions, unless otherwise noted. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-to-participate-in-upcoming-investor-conferences-302754983.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West to Participate in Upcoming Investor Conferences

West Reports First-Quarter 2026 ResultsApril 23, 2026 6:00 AM
PR Newswire (US)

Strong Start to the Year and Raising Full-Year Revenue and EPS guidanceEXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026.







First-Quarter Summary (comparisons to prior-year period)Net sales of $844.9 million increased 21.0%; organic growth was 15.3%.Diluted earnings per share ("EPS") of $1.92 increased 56.1%.Adjusted-diluted EPS of $2.13 increased 46.9%.Operating cash flow was $89.9 million. Capital expenditures were $42.7 million. Free cash flow (defined as operating cash flow less capital expenditures) was $47.2 million.The Company repurchased 1.2 million shares for $297.6 million at an average price of $243.57 per share under its share repurchase program that was announced in mid-February 2026.Outlook for Full-Year and Second Quarter 2026Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up from $3.215 billion to $3.275 billion and full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.40 to $8.75, up from $7.85 to $8.20.Second quarter 2026 net sales are expected to be in the range of $830 million to $850 million, up 8.3% to 10.9% reported and up 7.0% to 9.6% organic.Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: "I am pleased to report a very strong start to the year with revenues and adjusted EPS exceeding expectations. Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues. The better-than-expected performance can be attributed to continued market demand and the team's outstanding efforts in ramping up production, especially in Europe. As a result of these excellent first quarter results and expected continued momentum in our business, we are increasing our full-year 2026 guidance."Proprietary Products Segment
Net sales of $694.3 million grew by 23.3% and increased 17.5% on an organic basis.High-Value Product ("HVP") Components net sales of $409.3 million increased 29.6% and rose 22.6% on an organic basis driven by strength in Westar® and NovaPure® products. HVP Components accounted for 48% of total company net sales in the quarter.HVP Delivery Devices net sales of $123.6 million increased by 29.0%, and were up 27.5% on an organic basis, driven by increased sales of self-injection device platforms and Daikyo Crystal Zenith®. HVP Delivery Devices accounted for 15% of total company net sales in the quarter.Standard Products net sales of $161.4 million increased by 6.7% and rose 0.5% on an organic basis. Standard Products accounted for 19% of total company net sales this quarter.West Vantage Segment
Effective in the first quarter of 2026, the Company renamed its "Contract-Manufactured Products" reportable segment to "West Vantage™" to better align with its current strategic focus and offerings. This change in name does not affect the composition of the reportable segment, nor does it impact previously reported segment financial information. Net sales of $150.6 million increased by 11.6% and rose 6.2% on an organic basis. Segment performance was driven by an increase in sales of self-injection devices for obesity and diabetes. West Vantage accounted for 18% of total company net sales in the quarter.Full-Year 2026 Financial Guidance The Company is increasing its full-year 2026 net sales guidance range to $3.295 billion to $3.350 billion, which continues to assume a mid-year close for the sale of SmartDose® 3.5mL to Abbvie, up from $3.215 billion to $3.275 billion.Reported net sales growth is now anticipated to be in the range of 7.2% to 9.0%, and organic net sales growth is expected to be in the range of 7% to 9%.Net sales guidance includes an estimated full-year 2026 benefit of approximately 2 percentage points based on current foreign currency exchange rates.SmartDose® 3.5mL generated $55 million in revenues in the second half of 2025. These revenues are excluded to calculate our full-year 2026 organic revenue growth guidance.The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $8.40 to $8.75, up from the previous range of $7.85 to $8.20.Capital spending guidance is unchanged from a range of $250 million to $275 million.Second-Quarter 2026 Financial Guidance The Company is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million.Reported net sales growth anticipated to be in the range of 8.3% to 10.9%, organic net sales growth is expected to be in the range of 7.0% to 9.6%.Net sales guidance includes an estimated second-quarter 2026 benefit of approximately 1.3 percentage points based on current foreign currency exchange rates.The Company is introducing its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12, up 11.4% to 15.2%.First-Quarter 2026 Conference Call
Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website and by clicking here.To participate in the Q&A portion of the conference call, please register in advance by clicking here.Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.An accompanying slide presentation will be posted in the "Investors" section of the Company's website.A replay of the webcast will be available on the Company's website for approximately 90 days after the event.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "estimate," "plan," "anticipate," "project," "forecast," "guidance," "target," "may," "will," "continue" and similar expressions.These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company's most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Non-U.S. GAAP Financial Measures
The Company reports its financial results in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). However, management also uses certain non-U.S. GAAP financial measures in evaluating our results of operations. Management believes that this information provides users with a valuable insight into our overall performance and financial position. As a result, this release contains certain non-GAAP financial measures, including organic net sales, adjusted-diluted EPS and adjusted operating profit. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results, such as adjusted-diluted EPS and adjusted operating profit, that exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically identified income or expense items. These non-U.S. GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's results prepared in accordance with U.S. GAAP. A reconciliation of these non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.WEST PHARMACEUTICAL SERVICES, INC.CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)(in millions, except per share data)

Three Months Ended
March 31,
2026
2025Net sales$         844.9
100 %
$         698.0
100 %Cost of goods and services sold548.5
65
466.1
67Gross profit296.4
35
231.9
33Research and development15.8
2
16.3
2Selling, general and administrative expenses99.5
12
88.0
13Other expense (income), net4.0
—
20.6
3Operating profit177.1
21
107.0
15Interest (income) expense, net(3.2)
—
(3.7)
(1)Other nonoperating expense (income)0.2
—
0.2
—Income before income taxes and equity in
net income of affiliated companies180.1
21
110.5
16Income tax expense44.7
5
24.1
3Equity in net income of affiliated companies(3.4)
—
(3.4)
—Net income$         138.8
16 %
$           89.8
13 %







Net income per share:






Basic$           1.93


$           1.24

Diluted$           1.92


$           1.23









Average common shares outstanding72.0


72.5

Average shares assuming dilution72.4


73.0

WEST PHARMACEUTICAL SERVICESREPORTING SEGMENT INFORMATION(UNAUDITED)(in millions)

Three Months EndedMarch 31,Net Sales:2026
2025Proprietary Products$       694.3
$       563.0West Vantage150.6
135.0Consolidated Total$       844.9
$       698.0



Gross Profit:


Proprietary Products$       273.1
$       210.2West Vantage23.3
21.7Gross Profit$       296.4
$       231.9Gross Profit Margin35.1 %
33.2 %



Operating Profit (Loss):


Proprietary Products$       189.2
$       130.6West Vantage15.6
13.5Stock-based compensation expense(6.6)
(1.3)General corporate costs(21.1)
(35.8)Reported Operating Profit$       177.1
$       107.0Reported Operating Profit Margin21.0 %
15.3 %



Unallocated items3.9
18.0Adjusted Operating Profit$       181.0
$       125.0Adjusted Operating Profit Margin21.4 %
17.9 %WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS
Three Months ended March 31, 2026Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$177.1
$44.7
$138.8
$1.92Unallocated Items:






Restructuring and other charges (1)1.4
(11.6)
13.0
0.18SmartDose® 3.5mL sale (2)1.9
0.4
1.5
0.02Amortization of acquisition-related intangible assets (3)—
—
0.5
0.01Other0.6
0.2
0.5
—Adjusted (Non-U.S. GAAP)$181.0
$33.7
$154.3
$2.13
Three Months ended March 31, 2025Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$107.0
$24.1
$89.8
$1.23Unallocated items:






Restructuring and other charges (1)17.8
2.0
15.8
0.21Amortization of acquisition-related intangible assets (3)0.2
—
0.6
0.01Adjusted (Non-U.S. GAAP)$125.0
$26.1
$106.2
$1.45(1)During the three months ended March 31, 2026, the Company recorded pre-tax charges of $1.4 million related to our two existing restructuring programs: (i) $0.9 million within other expense (income), related to acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded a one-time tax cost of $12.0 million associated with an internal legal entity restructuring which occurred in the first quarter of 2026. During the three months ended March 31, 2025, the Company recorded pre-tax charges of $17.8 million related to our two existing restructuring programs: (i) $16.4 million within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $1.4 million within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded income tax charges of $2.0 million related primarily to withholding tax and capital gains incurred in executing our plan to optimize our legal structure.

(2)During the three months ended March 31, 2026, the Company recorded charges of $1.9 million related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $0.9 million of the charges within other expense (income), related to employee benefit costs in connection with the sale agreement. The Company recorded the remaining $1.0 million within selling, general and administrative expenses, relating to professional services in connection with the sale agreement.

(3)During the three months ended March 31, 2026, and 2025, the Company recorded $0.0 million and $0.2 million, respectively, of amortization expense within selling, general and administrative expenses associated with an intangible asset acquired during the second quarter of 2020. During the three months ended March 31, 2026, and 2025, the Company recorded $0.5 million and $0.4 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported Net Sales to Organic Net Sales by Segment (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

Proprietary Products$694.3$563.0
23.3 %
5.8 %17.5 %West Vantage150.6135.0
11.6 %
5.4 %6.2 %Total$844.9$698.0
21.0 %
5.7 %15.3 %
Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

HVP Components$409.3$315.9
29.6 %
7.0 %22.6 %HVP Delivery Devices123.695.8
29.0 %
1.5 %27.5 %Standard Products161.4151.3
6.7 %
6.2 %0.5 %Total Proprietary Products$694.3$563.0
23.3 %
5.8 %17.5 %
Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

Biologics$354.5$269.3
31.6 %
5.7 %25.9 %Pharma210.6180.6
16.6 %
6.8 %9.8 %Generics129.2113.1
14.2 %
4.4 %9.8 %Total Proprietary Products$694.3$563.0
23.3 %
5.8 %17.5 %
Reconciliation of Reported Net Sales to Organic Net Sales by Geography (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

Americas$377.3$338.9
11.3 %
0.5 %10.8 %Europe, Middle East, Africa399.4306.9
30.1 %
12.2 %17.9 %Asia Pacific68.252.2
30.7 %
1.4 %29.3 %Total$844.9$698.0
21.0 %
5.7 %15.3 %(4)Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period.WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance

2025 Actual
2026 Guidance
% ChangeReported-diluted EPS (U.S. GAAP)$6.79
$8.15 to $8.50
20.0% to 25.2%Restructuring and other charges0.31
0.21

SmartDose® 3.5mL sale0.09
0.02

Cost-method investment activity0.06
—

Amortization of acquisition-related intangible assets0.03
0.02

Other0.01
—

Adjusted-diluted EPS (Non-U.S. GAAP)$7.29
$8.40 to $8.75
15.2% to 20.0%WEST PHARMACEUTICAL SERVICESCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in millions, except per share data)March 31,
2026
December 31,
2025ASSETS


Current assets:


Cash and cash equivalents$         521.4
$         791.3Accounts receivable, net685.6
574.4Inventories452.6
443.9Other current assets167.2
168.6Total current assets1,826.8
1,978.2Property, plant and equipment3,223.0
3,223.4Less: accumulated depreciation and amortization1,520.8
1,497.0Property, plant and equipment, net1,702.2
1,726.4Operating lease right-of-use assets110.2
117.0Investments in affiliated companies209.2
212.3Goodwill109.2
109.9Intangible assets, net7.0
7.7Deferred income taxes63.9
38.4Other noncurrent assets81.3
80.1Total Assets$       4,109.8
$       4,270.0



LIABILITIES AND EQUITY


Current liabilities:


Accounts payable$          252.3
$          253.7Accrued salaries, wages and benefits72.6
135.9Income taxes payable78.9
28.1Operating lease liabilities21.4
22.7Accrued commissions, rebates and royalties46.6
39.2Other current liabilities202.2
175.3Total current liabilities674.0
654.9Long-term debt202.8
202.8Deferred income taxes22.7
23.0Pension and other postretirement benefits28.5
29.0Operating lease liabilities92.0
95.6Deferred compensation benefits11.8
13.5Other long-term liabilities87.6
75.2Total Liabilities1,119.4
1,094.0



Equity:


Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding—
—Common stock, par value $0.25 per share; 200.0 million shares authorized; shares
     issued: March 31, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares
     outstanding: March 31, 2026 - 70.9 million, December 31, 2025 - 72.0 million18.8
18.8Capital in excess of par value—
—Retained earnings4,475.9
4,374.9Accumulated other comprehensive loss(125.2)
(105.5)Treasury stock, at cost (March 31, 2026 - 4.4 million shares, December 31, 2025 -
     3.3 million shares)(1,379.1)
(1,112.2)Total Equity2,990.4
3,176.0Total Liabilities and Equity$       4,109.8
$       4,270.0WEST PHARMACEUTICAL SERVICESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(in millions)

Three Months Ended
March 31,
2026
2025Cash flows from operating activities:


Net income$         138.8
$           89.8Adjustments to reconcile net income to net cash provided by operating
activities:


Depreciation44.6
39.1Amortization0.6
0.9Stock-based compensation6.6
1.3Non-cash restructuring charges0.9
0.8Asset impairments0.3
0.3Other non-cash items, net1.0
(2.9)Changes in assets and liabilities(102.9)
0.1Net cash provided by operating activities89.9
129.4



Cash flows from investing activities:


Capital expenditures(42.7)
(71.3)Net cash used in investing activities(42.7)
(71.3)



Cash flows from financing activities:


Principal repayments on finance leases(0.3)
(0.2)Dividend payments(15.8)
(15.2)Proceeds from stock-based compensation awards5.5
2.5Employee stock purchase plan contributions2.0
1.9Shares purchased under share repurchase programs(297.6)
(133.5)Shares repurchased for employee tax withholdings(2.5)
(2.5)Net cash used in financing activities(308.7)
(147.0)Effect of exchange rates on cash(8.4)
8.5Net decrease in cash and cash equivalents(269.9)
(80.4)



Cash, including cash equivalents at beginning of period791.3
484.6Cash, including cash equivalents at end of period$         521.4
$         404.2



Supplemental cash flow information:


    Accrued capital expenditures$           26.1
$           37.5 



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-reports-first-quarter-2026-results-302751100.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West Reports First-Quarter 2026 Results

West to Host First-Quarter 2026 Conference CallApril 9, 2026 6:00 AM
PR Newswire (US)

EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.







The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call. A slide presentation will be made available on the day of the call in the Investors section of the Company's website. A replay of the webcast will be available on the Company's website for approximately 90 days after the event.About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-to-host-first-quarter-2026-conference-call-302737277.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West to Host First-Quarter 2026 Conference Call

West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and ObesityMarch 31, 2026 11:46 AM
PR Newswire (US)

EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity.







"West is honored to continue supporting our customers in providing reliable, high-quality drug delivery solutions and security of supply," said Aileen Ruff-Patry, President of Contract Manufacturing at West. "This expansion increases our global capacity to support drug handling for high-volume injectable therapies, including next-generation GLP-1 treatments. This reinforces West's role as a critical partner in helping to secure patient access to these essential medicines."As demand for complex injectable drug delivery systems continues to grow, access to integrated development and commercialization services to support these products becomes increasingly critical. The Damastown expansion enhances West's contract capabilities beyond its component molding, device assembly, and packaging to now include advanced automation and expanded drug-handling capabilities at commercial scale.The work at this site is part of West Vantage™, the company's comprehensive contract services business. West Vantage™ provides customers with a single-source solution spanning product conceptualization, development, device manufacturing and assembly, packaging, validation, analytical testing, and regulatory support. Through this integrated approach, West helps pharmaceutical and biotechnology partners accelerate time to market by delivering reliable, scalable solutions that support the global supply of life-enhancing and life-saving therapies.About West 
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE:?WST) and is included in the Standard & Poor's 500 index. For more information, visit?www.westpharma.com.?










View original content to download multimedia:https://www.prnewswire.com/news-releases/west-expands-dublin-facility-to-support-high-volume-injectable-therapies-including-diabetes-and-obesity-302730303.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity

Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc.March 9, 2026 4:30 PM
PR Newswire (US)

EXTON, Pa., March 9, 2026  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. In parallel with today's announcement, the Company is reaffirming the guidance set forth in its February 12, 2026 press release.







"After serving 11 years as the Company's 6th CEO over the past century, it is time for someone else to take over the leadership of West," Green said.  "I have great confidence in the strong leadership team we have in place to carry on with the current momentum to take this extraordinary Company forward.  I am especially thankful to the Board of Directors for giving me this stewardship to lead West over more than a decade and for their support of my decision. My decision provides the opportunity to serve in the future in other capacities, including corporate boards and advisory roles.""We are grateful to Eric for his remarkable service to West," said Robert F. Friel, Lead Independent Director of the Board of Directors. "His eleven-year tenure is marked by exceptional revenue and enterprise value growth, having more than doubled the sales of the Company during that time and achieved total shareholder return of approximately 350%.""In addition to these accomplishments, during Eric's tenure the Company drove innovations that uniquely meet patients' needs, responded to the unprecedented COVID pandemic by supporting the delivery of vaccines around the world, and significantly grew our global impact.""As the leading provider of innovative, high-quality injectable solutions and services, the Company is in an excellent position to achieve its long-term growth ambitions and to continue to create value for patients, customers and shareholders," Green added.Green has served as President and Chief Executive Officer of West since April 2015, and he became Chair of the Board in May 2022.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "estimate," "plan," "anticipate," "project," "forecast," "guidance," "target," "may," "will," "continue" and similar expressions.These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company's most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 










View original content to download multimedia:https://www.prnewswire.com/news-releases/eric-m-green-informs-board-of-plans-to-retire-as-president-ceo-and-chair-of-the-board-of-west-pharmaceutical-services-inc-302708557.htmlSOURCE West Pharmaceutical Services, Inc.

Original: Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc.

West to Participate in Upcoming Investor ConferencesFebruary 27, 2026 6:00 AM
PR Newswire (US)

EXTON, Pa., Feb. 27, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences:







Barclays Global Healthcare Conference: Fireside chat at 9:00 AM EDT on Tuesday, March 10, 2026KBCM Healthcare Forum: Fireside chat at 1:30 PM EDT on Wednesday, March 18, 2026The live webcasts for these events can be accessed in the Investors section of the Company's website. A replay of each webcast will also be available on the Company's website for approximately 90 days after each respective event. About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of?West Pharmaceutical Services, Inc.?or its subsidiaries, in?the United States?and other jurisdictions, unless otherwise noted. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-to-participate-in-upcoming-investor-conferences-302699215.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West to Participate in Upcoming Investor Conferences

West Announces Quarterly Dividend and Share Repurchase ProgramFebruary 17, 2026 4:00 PM
PR Newswire (US)

EXTON, Pa., Feb. 17, 2026 /PRNewswire/ -- On February 16, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on May 6, 2026 to shareholders of record on April 29, 2026.







On February 17, 2026, the Board of Directors authorized a new share repurchase program for the purchase of up to $1 billion of the Company's common stock.The number of shares to be repurchased and the timing of any repurchases will depend on factors such as the stock price, economic and market conditions, and corporate and regulatory requirements. The Company may repurchase shares of its common stock from time to time on the open market (including via pre-set trading plans), in privately negotiated transactions, or through other transactions in accordance with applicable securities laws. The share repurchase program does not obligate the Company to acquire any particular amount of common stock, has no expiration date, and it may be suspended or terminated at any time.The Company's previous share repurchase program was fully utilized prior to its December 31, 2025, expiration.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life saving and life enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of?West Pharmaceutical Services, Inc.?or its subsidiaries, in?the United States?and other jurisdictions, unless otherwise noted.  



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-announces-quarterly-dividend-and-share-repurchase-program-302689836.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West Announces Quarterly Dividend and Share Repurchase Program

West Pharma Gains More Than 5% After Q4 Earnings OutperformFebruary 12, 2026 8:34 AM
IH Market News
West Pharmaceutical Services Inc (NYSE:WST) advanced over 5% in premarket trading Thursday after reporting fourth-quarter results that topped analyst projections, supported by robust demand for its higher-margin product lines.The injectable drug packaging and delivery specialist posted adjusted earnings of $2.04 per share for the quarter, comfortably above the $1.84 consensus estimate. Revenue reached $805 million, exceeding expectations of $796.25 million and marking a 7.5% increase year over year. Organic growth for the quarter was 3.3%.Performance was driven largely by the company’s High-Value Product Components segment, which recorded 20.3% growth, including 15.1% organic expansion. Strength in Westar and Envision product lines contributed significantly to the results.“Our strong finish to 2025 was a result of the team’s relentless execution of our growth strategy,” said Eric M. Green, West’s President, Chief Executive Officer and Chair of the Board. “Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth.”Looking ahead, West issued upbeat guidance for fiscal 2026. The company expects adjusted earnings per share in the range of $7.85 to $8.20, ahead of the $7.76 analyst consensus. Full-year 2026 net sales are projected between $3.215 billion and $3.275 billion, implying organic growth of 5% to 7%.For the first quarter of 2026, management forecasts net sales of $770 million to $790 million and adjusted EPS of $1.65 to $1.70.For full-year 2025, West reported net sales of $3.074 billion, up 6.3% from the prior year, with organic growth of 4.3%. Adjusted EPS for the year totaled $7.29, reflecting an 8% increase compared with 2024.West Pharmaceutical Services stock price

Original: West Pharma Gains More Than 5% After Q4 Earnings Outperform

West Reports Fourth-Quarter and Full-Year 2025 ResultsFebruary 12, 2026 6:00 AM
PR Newswire (US)

– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components –– Introduces Fiscal 2026 Financial Guidance –EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025.







Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period)Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per share (EPS) of $1.82 increased 2.2%.Fourth-quarter Adjusted-diluted EPS of $2.04 increased 12.1%.Full-year net sales of $3.074 billion increased 6.3%; organic growth was 4.3%.Full-year Diluted EPS of $6.79 increased 1.5%.Full-year Adjusted-diluted EPS of $7.29 increased 8.0%.Operating cash flow was $754.8 million, an increase of 15.5%. Capital expenditures were $285.9 million. Free cash flow (defined as operating cash flow less capital expenditures) was $468.9 million, an increase of 69.6%.During 2025, the Company repurchased 552,593 shares for $134.0 million at an average share price of $242.55 under its share repurchase programs."Our strong finish to 2025 was a result of the team's relentless execution of our growth strategy," said Eric M. Green, West's President, Chief Executive Officer and Chair of the Board. "Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders."Proprietary Products Segment
Fourth-quarter net sales of $661.8 million grew by 7.8% and increased 3.6% on an organic basis.High-Value Product ("HVP") Components net sales of $389.8 million increased 20.3% and grew 15.1% on an organic basis driven by strength in Westar® and Envision® products. HVP Components accounted for 48% of total company net sales in the quarter.HVP Delivery Devices net sales of $110.4 million decreased by 16.9%, and were down 18.1% on an organic basis, driven by the previously disclosed non-recurring incentive fee of $25 million earned in the fourth quarter of 2024. HVP Delivery Devices accounted for 14% of total company net sales in the quarter.Standard Products net sales of $161.6 million increased by 3.0%, but declined 1.7% on an organic basis. Standard Products accounted for 20% of total company net sales this quarter.Contract-Manufactured Products Segment
Fourth-quarter 2025 net sales increased by 6.2% to $143.2 million, while organic net sales grew 1.9%. Segment performance was driven by growth in self-injection devices for obesity and diabetes, partially offset by a continued decrease in sales of healthcare diagnostic devices.  Contract Manufacturing accounted for 18% of total company net sales in the quarter.Introducing Full-Year and First-Quarter 2026 Financial GuidanceFull-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie.Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%.Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates.SmartDose® 3.5mL generated $55 million in revenues in the second half of 2025. These revenues are excluded to calculate our full-year 2026 organic revenue growth guidance.Full-year 2026 adjusted-diluted EPS is expected to be in a range of $7.85 to $8.20, representing growth of 7.7% to 12.5%.Full-year 2026 capital expenditures are expected to be in the range of $250 million to $275 million.First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%.First-quarter adjusted-diluted EPS is expected to be in the range of $1.65 to $1.70, up 13.0% to 16.4%.Fourth-Quarter and Full-Year 2025 Conference Call 
Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website and by clicking here.To participate in the Q&A portion of the conference call, please register in advance by clicking here.Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.An accompanying slide presentation will be posted in the "Investors" section of the Company's website.A replay of the webcast will be available on the Company's website for approximately 90 days after the event.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.Forward-Looking Statements
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include such words as "expected," "assumes," "unchanged," "includes," "would," "provide" and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; customers' changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories; disruptions or limitations in the Company's manufacturing capacity; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; increased raw material, energy and labor costs; fluctuations in currency exchange; the ability to meet development milestones with key customers; and the consequences of other geopolitical events, including natural disasters, acts of war, and global health crises. This list of important factors is not all inclusive. For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, see Part I Item 1A, entitled "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the United States Securities and Exchange Commission, including the Company's quarterly reports on Form 10-Q and current reports on Form 8-K.Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Non-U.S. GAAP Financial Measures
This release contains certain financial measures outside of generally accepted accounting principles ("U.S. GAAP"), including organic net sales and adjusted-diluted EPS. For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation and excluding the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.WEST PHARMACEUTICAL SERVICES, INC.CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)(in millions, except per share data)

Three Months Ended
December 31,
Twelve Months Ended
December 31,
2025
2024
2025
2024Net sales$     805.0
100 %
$     748.8
100 %
$  3,074.1
100 %
$  2,893.2
100 %Cost of goods and services sold501.1
62
475.2
63
1,970.1
64
1,894.7
65Gross profit303.9
38
273.6
37
1,104.0
36
998.5
35Research and development21.8
3
18.5
3
74.3
2
69.1
2Selling, general and administrative
expenses107.0
14
85.3
12
393.6
13
338.5
12Other expense (income), net18.5
2
10.2
1
51.2
2
21.0
1Operating profit156.6
19
159.6
21
584.9
19
569.9
20Interest (income) expense, net(5.3)
(1)
(5.6)
(1)
(17.0)
(1)
(16.6)
—Other nonoperating expense
(income)0.4
—
0.3
—
1.0
—
1.0
—Income before income taxes and
equity in net income of affiliated
companies161.5
20
164.9
22
600.9
20
585.5
20Income tax expense33.3
4
36.8
4
121.6
4
107.5
4Equity in net income of affiliated
companies(3.9)
—
(2.0)
—
(14.4)
—
(14.7)
(1)Net income$     132.1
16 %
$     130.1
18 %
$     493.7
16 %
$     492.7
17 %















Net income per share:














Basic$       1.83


$       1.79


$       6.83


$       6.75

Diluted$       1.82


$       1.78


$       6.79


$       6.69

















Average common shares
outstanding72.3


72.7


72.3


73.0

Average shares assuming dilution72.7


73.3


72.7


73.7

















 WEST PHARMACEUTICAL SERVICESREPORTING SEGMENT INFORMATION(UNAUDITED)(in millions)

Three Months EndedDecember 31,
Twelve Months EndedDecember 31,Net Sales:2025
2024
2025
2024Proprietary Products$          661.8
$          613.9
$       2,492.1
$       2,334.5Contract-Manufactured Products143.2
134.9
582.0
558.7Consolidated Total$          805.0
$          748.8
$       3,074.1
$       2,893.2







Gross Profit:






Proprietary Products$          285.7
$          250.7
$       1,008.2
$          900.5Contract-Manufactured Products18.2
22.9
95.8
98.0Gross Profit$          303.9
$          273.6
$       1,104.0
$          998.5Gross Profit Margin37.8 %
36.5 %
35.9 %
34.5 %







Operating Profit (Loss):






Proprietary Products$          189.7
$          162.3
$          657.2
$          577.8Contract-Manufactured Products9.8
16.2
63.4
72.3Stock-based compensation expense(6.7)
(4.3)
(23.8)
(18.7)General corporate costs(36.2)
(14.6)
(111.9)
(61.5)Reported Operating Profit$          156.6
$          159.6
$          584.9
$          569.9Reported Operating Profit Margin19.5 %
21.3 %
19.0 %
19.7 %







Unallocated items15.4
3.2
37.5
2.9Adjusted Operating Profit$          172.0
$          162.8
$          622.4
$          572.8Adjusted Operating Profit Margin21.4 %
21.7 %
20.2 %
19.8 % WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPSThree Months ended December 31, 2025Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$156.6
$33.3
$132.1
$1.82Unallocated items:






Restructuring and other charges (1)1.4
(2.1)
3.4
0.05SmartDose® 3.5mL sale (2)8.4
1.9
6.5
0.09Cost-method investment activity (3)4.5
—
4.5
0.06Amortization of acquisition-related intangible assets (4)—
—
0.5
0.01Other1.1
0.3
0.8
0.01Adjusted (Non-U.S. GAAP)$172.0
$33.4
$147.8
$2.04
Twelve Months ended December 31, 2025Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$584.9
$121.6
$493.7
$6.79Unallocated items:






Restructuring and other charges (1)23.3
0.9
22.4
0.31SmartDose® 3.5mL sale (2)8.4
1.9
6.5
0.09Cost-method investment activity (3)4.5
—
4.5
0.06Amortization of acquisition-related intangible assets (4)0.2
—
2.0
0.03Other1.1
0.3
0.8
0.01Adjusted (Non-U.S. GAAP)$622.4
$124.7
$529.9
$7.29
Three Months ended December 31, 2024Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$159.6
$36.8
$130.1
$1.78Unallocated items:






Restructuring and other charges (1)3.0
0.7
2.3
0.03Amortization of acquisition-related intangible assets (4)0.2
—
0.7
0.01Adjusted (Non-U.S. GAAP)$162.8
$37.5
$133.1
$1.82
Twelve Months ended December 31, 2024Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$569.9
$107.5
$492.7
$6.69Unallocated items:






Restructuring and other charges (1)2.1
0.4
1.7
0.02Amortization of acquisition-related intangible assets (4)0.8
0.1
2.8
0.04Adjusted (Non-U.S. GAAP)$572.8
$108.0
$497.2
$6.75

(1)During the three and twelve months ended December 31, 2025, the Company recorded pre-tax charges of $1.4 million and $23.3 million, respectively, related to our two existing restructuring programs: (i) 0.9 million and $18.4 million in the three and twelve months ended December 31, 2025, respectively, within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $4.9 million in the three and twelve months ended December 31, 2025, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded income tax charges of $2.3 million and $4.9 million during the three and twelve months ended December 31, 2025, respectively, related primarily to withholding tax and capital gains incurred in executing our plan to optimize our legal structure. During the three and twelve months ended December 31, 2024, the Company recorded expense to restructuring and other charges of $3.0 million and $2.1 million, respectively. The net expense represents the impact of two items, the first of which is an expense $3.0 million and $4.6 million during the three and twelve months ended December 31, 2024, respectively, recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consisted primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit in the twelve months ended December 31, 2024 recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan.(2)During the three and twelve months ended December 31, 2025, the Company recorded charges of $8.4 million related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $6.2 million of the charges within other expense (income), related to severance and lease impairment charges in connection with the sale agreement. The Company recorded the remaining $2.2 million within selling, general and administrative expenses, relating to professional services in connection with the sale agreement.(3)During the three and twelve months ended December 31, 2025, the Company recorded cost-method investment impairment charges of $4.5 million within other expense (income).(4)During the three and twelve months ended December 31, 2025 and 2024, the Company recorded $0.0 million and $0.2 million, and $0.2 million and $0.8 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and twelve months ended December 31, 2025 and 2024, the Company recorded $0.5 million and $1.8 million, and $0.5 million and $2.1 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported Net Sales to Organic Net Sales by Segment(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Proprietary Products$661.8$613.9
7.8 %
4.2 %3.6 %Contract-Manufactured Products143.2134.9
6.2 %
4.3 %1.9 %Total$805.0$748.8
7.5 %
4.2 %3.3 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Proprietary Products$2,492.1$2,334.5
6.8 %
2.0 %4.8 %Contract-Manufactured Products582.0558.7
4.2 %
2.1 %2.1 %Total$3,074.1$2,893.2
6.3 %
2.0 %4.3 % Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

HVP Components$389.8$324.1
20.3 %
5.2 %15.1 %HVP Delivery Devices110.4132.9
(16.9) %
1.2 %(18.1) %Standard Products161.6156.9
3.0 %
4.7 %(1.7) %Total Proprietary Products$661.8$613.9
7.8 %
4.2 %3.6 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

HVP Components$1,451.0$1,305.0
11.2 %
2.3 %8.9 %HVP Delivery Devices406.4404.5
0.5 %
0.8 %(0.3) %Standard Products634.7625.0
1.6 %
1.9 %(0.3) %Total Proprietary Products$2,492.1$2,334.5
6.8 %
2.0 %4.8 % Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Biologics$340.4$305.2
11.5 %
4.2 %7.3 %Pharma191.5181.6
5.5 %
5.2 %0.3 %Generics129.9127.1
2.2 %
2.8 %(0.6) %Total Proprietary Products$661.8$613.9
7.8 %
4.2 %3.6 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Biologics$1,226.5$1,116.6
9.8 %
2.1 %7.7 %Pharma753.1712.4
5.7 %
2.3 %3.4 %Generics512.5505.5
1.4 %
0.8 %0.6 %Total Proprietary Products$2,492.1$2,334.5
6.8 %
2.0 %4.8 % Reconciliation of Reported Net Sales to Organic Net Sales by Geography(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Americas$358.6$354.8
1.1 %
0.4 %0.7 %Europe, Middle East, Africa370.2323.0
14.6 %
9.5 %5.1 %Asia Pacific76.271.0
7.3 %
(1.0) %8.3 %Total$805.0$748.8
7.5 %
4.2 %3.3 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Americas$1,422.5$1,311.9
8.4 %
(0.2) %8.6 %Europe, Middle East, Africa1,387.91,323.5
4.9 %
4.7 %0.2 %Asia Pacific263.7257.8
2.3 %
(1.5) %3.8 %Total$3,074.1$2,893.2
6.3 %
2.0 %4.3 %

(5)Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance
2025 Actual
2026 Guidance
% ChangeReported-diluted EPS (U.S. GAAP)$6.79
$7.79 to $8.14
14.7% to 19.9%Restructuring and other charges0.31
0.04

SmartDose® 3.5mL sale0.09
—

Cost-method investment activity0.06
—

Amortization of acquisition-related intangible assets0.03
0.02

Other0.01
—

Adjusted-diluted EPS (Non-U.S. GAAP)$7.29
$7.85 to $8.20
7.7% to 12.5%
Notes: See "Introducing Full-Year and First-Quarter 2026 Financial Guidance" and "Non-U.S. GAAP Financial Measures" in today's press release for additional information regarding adjusted-diluted EPS. WEST PHARMACEUTICAL SERVICESCONSOLIDATED BALANCE SHEETS
 (in millions, except per share data)2025
2024ASSETS


Current assets:


Cash and cash equivalents$            791.3
$            484.6Accounts receivable, net574.4
552.5Inventories443.9
377.0Other current assets168.6
124.0Total current assets1,978.2
1,538.1Property, plant and equipment3,223.4
2,985.8Less: accumulated depreciation and amortization1,497.0
1,404.2Property, plant and equipment, net1,726.4
1,581.6Operating lease right-of-use assets117.0
104.5Investments in affiliated companies212.3
202.1Goodwill109.9
106.0Intangible assets, net7.7
10.8Deferred income taxes38.4
26.0Other noncurrent assets80.1
74.3Total Assets$         4,270.0
$         3,643.4



LIABILITIES AND EQUITY


Current liabilities:


Accounts payable253.7
239.3Accrued salaries, wages and benefits135.9
73.5Income taxes payable28.1
31.5Operating lease liabilities22.7
17.9Other current liabilities214.5
188.2Total current liabilities654.9
550.4Long-term debt202.8
202.6Deferred income taxes23.0
20.5Pension and other postretirement benefits29.0
28.2Operating lease liabilities95.6
81.8Deferred compensation benefits13.5
15.4Other long-term liabilities75.2
62.2Total Liabilities1,094.0
961.1



Commitments and contingencies (Note 18)






Equity:


Preferred stock, 3.0 million shares authorized; 0.0 shares issued and
outstanding in 2025 and 2024—
—Common stock, par value $0.25 per share; 200 million shares authorized;
shares issued: 75.3 million in 2025 and 2024; shares outstanding: 72.0 million
and 72.3 million in 2025 and 202418.8
18.8Capital in excess of par value—
22.1Retained earnings4,374.9
3,956.6Accumulated other comprehensive loss(105.5)
(258.1)Treasury stock, at cost (3.3 million and 3.0 million shares in 2025 and 2024)(1,112.2)
(1,057.1)Total Equity3,176.0
2,682.3Total Liabilities and Equity$         4,270.0
$         3,643.4 WEST PHARMACEUTICAL SERVICESCONSOLIDATED STATEMENTS OF CASH FLOWS(in millions)

Twelve Months Ended
December 31,
2025
2024Cash flows from operating activities:


Net income$              493.7
$              492.7Adjustments to reconcile net income to net cash provided by operating activities:


Depreciation168.6
151.8Amortization2.8
3.6Stock-based compensation23.8
18.7Non-cash restructuring charges5.4
—Asset impairments11.7
7.3Deferred income taxes(13.7)
(3.5)Pension and other retirement plans, net0.6
(2.0)Equity in undistributed earnings of affiliates, net of dividends(10.5)
(13.4)Other, net(7.4)
(4.7)Changes in assets and liabilities:


Decrease (increase) in accounts receivable6.9
(58.8)(Increase) decrease in inventories(62.8)
42.0(Increase) decrease in other current assets9.7
(5.8)Increase in accounts payable17.9
2.9Changes in other assets and liabilities108.1
22.6Net cash provided by operating activities754.8
653.4Cash flows from investing activities:


Capital expenditures(285.9)
(377.0)Other, net—
(1.7)Net cash used in investing activities(285.9)
(378.7)Cash flows from financing activities:


Borrowings of long-term debt—
164.7Repayments of long-term debt—
(169.0)Principal repayments on finance leases(1.1)
(23.3)Dividend payments(61.2)
(59.1)Excise tax payments(4.2)
(2.0)Proceeds from stock-based compensation awards11.3
25.5Employee stock purchase plan contributions6.9
7.2Shares purchased under share repurchase programs(134.0)
(560.9)Shares repurchased for employee tax withholdings(2.8)
(5.7)Net cash used in financing activities(185.1)
(622.6)Effect of exchange rates on cash22.9
(21.4)Net increase (decrease) in cash and cash equivalents306.7
(369.3)Cash, including cash equivalents at beginning of period484.6
853.9Cash, including cash equivalents at end of period$              791.3
$              484.6



Supplemental cash flow information:


Interest paid, net of amounts capitalized$                  0.3
$                  0.5Income taxes paid, net$              125.2
$                71.4Accrued capital expenditures$                37.9
$                53.0Dividends declared, not paid$                15.8
$                15.2 



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-reports-fourth-quarter-and-full-year-2025-results-302685827.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West Reports Fourth-Quarter and Full-Year 2025 Results

West to Host Fourth-Quarter and Full-Year 2025 Conference CallJanuary 29, 2026 6:00 AM
PR Newswire (US)

EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.







The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call. A slide presentation will be made available on the day of the call in the Investors section of the Company's website. A replay of the webcast will be available on the Company's website for approximately 90 days after the event.About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/west-to-host-fourth-quarter-and-full-year-2025-conference-call-302673246.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West to Host Fourth-Quarter and Full-Year 2025 Conference Call

News: $WST West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend

EXTON, Pa. , July 25, 2019 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2019 and updated full-year 2019 financial guidance. Second-Quarter 2019 Summary (comparisons to prior-year period) Net ...

Got this from West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend

News: $WST West Announces First-Quarter 2019 Results

EXTON, Pa. , April 25, 2019 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2019 and updated full-year 2019 financial guidance. First-Quarter 2019 Summary (comparisons to prior-year period) Net s...

Got this from https://marketwirenews.com/news-releases/west-announces-first-quarter-2019-results-8055780.html

Chart Looks like a W

Exciting market overview provided by West Pharmaceuticals Director of Product Management at SMi's 10th Annual European summit on Pre-Filled Syringes next Jan. Interesting talk on current trends and new tech. http://www.pre-filled-syringes.com/ihub

100 is getting near.....

West Pharmaceutical beats Street 3Q forecasts


October 27, 2016






EXTON, Pa. (AP) _ West Pharmaceutical Services Inc. (WST) on Thursday reported third-quarter earnings of $37.6 million.
On a per-share basis, the Exton, Pennsylvania-based company said it had profit of 50 cents. Earnings, adjusted for restructuring costs and pretax expenses, were 53 cents per share.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 52 cents per share.
The medical device company posted revenue of $376.7 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $372.7 million.
West Pharmaceutical shares have climbed 17 percent since the beginning of the year. The stock has climbed 23 percent in the last 12 months.

West Pharmaceutical upgraded to Outperform from Market Perform at Wells FargoWells Fargo analyst Tim Evans upgraded West Pharmaceutical Services to Outperform saying the company's "strong" quarter provided clear messaging around its margin trajectory. The analyst believes the margin story is now de-risked and he finds the entry point compelling with the stock down 13% from recent highs. Evans keeps an $80-$85 price target range for the shares.

Read more at:
http://thefly.com/landingPageNews.php?id=2452168

Smithers Rapra have forecast the global market for Pre-Filled Syringes to rise to $6.6 Billion by 2020. Good news for West!

Excited to hear more insight from their Director of Global Product Management in Pre-filled Systems and Delivery - Christa Jansen-Otten, when she presents in Central London at Pre-Filled Syringes Europe.

Details on the event in Jan 2017 are available at http://www.pre-filled-syringes.com/ihub

West downgraded to hold and sell

http://www.tickerreport.com/banking-finance/2171151/west-pharmaceutical-services-inc-wst-downgraded-to-sell-at-zacks-investment-research.html

I live 7 miles from the Clearwater plant This stock has always split when it gets to these prices.The new ceo has made a huge impact look for a long run up

Still low
Brother still working for wst, good future

This is the twenty-fourth consecutive annual increase in the Company's dividend

WST INCREASES DIVIDEND BY 8%
http://www.westpharma.com/en/Investors/Pages/NewsReleases.aspx?reqtype=releasetxt&reqid=2201042

http://www.nytimes.com/2016/09/03/us/politics/hillary-clinton-epipen-mylan.html?_r=0

http://www.westpharma.com/en/videos/Pages/TechGroup.aspx

WST up over 30% per year for last 5 years !!!!

Typical WST action.... Market down two days in a row and WST up two days in a row..

West Pharmaceutical Services Inc. (WST) Sets New 12-Month High at $81.80

August 6th, 2016 - 0 comments - Filed Under - by Latisha Jones










West Pharmaceutical Services logoWest Pharmaceutical Services Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $81.80 and last traded at $81.80, with a volume of 97,633 shares traded. The stock had previously closed at $80.96.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a research report on Wednesday, April 20th. Jefferies Group reaffirmed a “hold” rating on shares of West Pharmaceutical Services in a research report on Thursday. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $90.00 price objective (up from $69.00) on shares of West Pharmaceutical Services in a research report on Friday, May 13th.

West Pharmaceutical Services Inc. (NYSE:WST) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The brokerage presently has a $91.00 target price on the stock. Zacks Investment Research’s target price would suggest a potential upside of 11.66% from the company’s current price

http://baseballnewssource.com/markets/west-pharmaceutical-services-inc-wst-upgraded-by-zacks-investment-research-to-buy/59666/

http://www.westpharma.com/en/about/Pages/GlobalFacilities.aspx

another split coming??
Last two times this stock price topped 60 dollars it split 2 for 1 looks prime for another!!

This has turned out to be BIG for west...
http://www.pharmaasia.com/2015/04/eric-green-is-new-ceo-at-west-pharma/

West also increases year end outlook.

West now up over 2.5% percent for the day off great quarterly report

West teams up with Amgen

West beats by 4 cents

$WST DD Notes ~ http://www.ddnotesmaker.com/WST

bullish very long term

$WST recent news/filings

## source: finance.yahoo.com

Thu, 23 Oct 2014 12:52:45 GMT ~ West to Host Third Quarter 2014 Conference Call

[at noodls] - EXTON, PA -- (Marketwired) -- 10/23/14 -- (NYSE: WST) today that it will release third quarter 2014 financial results before the market opens on Thursday, October 30, 2014 and will follow with a conference ...

read full: http://www.noodls.com/view/0BEE0F66A6BFF2C9D7A938147A9B2D3E769763E6
*********************************************************

Thu, 23 Oct 2014 12:00:00 GMT ~ West to Host Third Quarter 2014 Conference Call

[Marketwired] - West Pharmaceutical Services, Inc. today that it will release third quarter 2014 financial results before the market opens on Thursday, October 30, 2014 and will follow with a conference call to discuss ...

read full: http://finance.yahoo.com/news/west-host-third-quarter-2014-120000963.html
*********************************************************

Tue, 21 Oct 2014 12:26:32 GMT ~ West's Vial2Bag DC Device Receives U.S. FDA 510(k) Clearance and CE Mark

[at noodls] - EXTON, Pa., Oct. 21, 2014 /PRNewswire/ -- (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has received 510(k) clearance of the Vial2Bag® DC device from the United ...

read full: http://www.noodls.com/view/D87AD234C5F0952A6D7116757AB79450A33DA934
*********************************************************

Tue, 21 Oct 2014 12:00:00 GMT ~ West's Vial2Bag DC Device Receives U.S. FDA 510(k) Clearance and CE Mark

[PR Newswire] - EXTON, Pa., Oct. 21, 2014 /PRNewswire/ -- West Pharmaceutical Services, Inc. (WST), a global leader in innovative solutions for injectable drug administration, has received 510(k) clearance of the Vial2Bag® DC device from the United States Food and Drug Administration, and also the CE Mark for the European Union. The Vial2Bag DC device is produced by West's subsidiary, Medimop Medical Projects Ltd., and is a universal admixture device designed to enable safe, convenient, needle-free reconstitution and transfer of drug products between a vial and a standard IV bag or bottle. Our new Vial2Bag DC device simplifies the IV admixture process and eliminates the risk of needlestick injuries and minimizes potential drug exposure, making this procedure safer and more efficient for healthcare staff," said John Paproski, President, Pharmaceutical Delivery Systems, West Pharmaceutical Services. Progressive Medical Inc. (PMI) will distribute the Vial2Bag DC device to hospitals in the United States.

read full: http://finance.yahoo.com/news/wests-vial2bag-dc-device-receives-120000003.html
*********************************************************

Wed, 15 Oct 2014 14:23:13 GMT ~ West Pharmaceutical Services Warns On FY14, CEO To Retire


read full: http://finance.yahoo.com/news/west-pharmaceutical-services-warns-fy14-142313742.html
*********************************************************


$WST charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$WST company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/WST/company-info
Ticker: $WST
OTC Market Place: Not Available
CIK code: 0000105770
Company name: West Pharmaceutical Services, Inc.
Company website: http://www.westpharma.com
Incorporated In: PA, USA


$WST share structure

## source: otcmarkets.com

Market Value: $3,246,684,941 a/o Oct 27, 2014
Shares Outstanding: 70,764,711 a/o Jun 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 2.05
$WST extra dd links

Company name: West Pharmaceutical Services, Inc.
Company website: http://www.westpharma.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/WST/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/WST/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=WST+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=WST+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=WST+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/WST/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/WST/news - http://finance.yahoo.com/q/h?s=WST+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/WST/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/WST/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/WST/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/WST/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/WST/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/WST/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/WST/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/WST/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=WST+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/WST
DTCC (dtcc.com): http://search2.dtcc.com/?q=West+Pharmaceutical+Services%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=West+Pharmaceutical+Services%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=West+Pharmaceutical+Services%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.westpharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.westpharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.westpharma.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/WST/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/WST
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/WST/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/WST/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/WST/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000105770&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/WST/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/WST/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/WST/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/WST/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=WST&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=WST
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/WST/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=WST+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=WST+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=WST
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=WST
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=WST+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/WST/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=WST+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/WST.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=WST
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/WST/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/WST/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/WST/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/WST/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/WST
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/WST
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/WST:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=WST
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=WST



$WST DD Notes ~ http://www.ddnotesmaker.com/WST

~ Thursday! $WST ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $WST ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=WST&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=WST&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=WST
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=WST#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=WST+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=WST
Finviz: http://finviz.com/quote.ashx?t=WST
~ BusyStock: http://busystock.com/i.php?s=WST&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=WST >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

West Breaks Ground for its Second Manufacturing Plant in China

West to Present at Jefferies Conference

West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Tuesday 31 May 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will attend the Jefferies 2011 Global Healthcare Conference in New York, NY. Management will present an overview of West's business and outlook on Monday, June 6, 2011 at 4:00 PM ET.

West Announces Third Quarter 2011 Dividend

West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Friday 6 May 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors has approved payment of the third-quarter 2011 cash dividend of $0.17 per share. The dividend will be paid on August 3, 2011 to shareholders of record on July 20, 2011

West Announces First Quarter 2011 Results

West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Thursday 28 April 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first quarter of 2011. Summary comparative results were as follows:


($ millions, except per-share data )
Three Months Ended

March 31,

2011
2010


Net Sales
$ 295.4
$ 274.7

Gross Profit
88.0
82.2

Reported Operating Profit
28.8
28.9

Adjusted Operating Profit (1)
30.7
29.5

Reported Diluted EPS
$ 0.56
$ 0.57

Adjusted Diluted EPS(1)
$ 0.60
$ 0.58



(1) See "Restructuring and Other Items" section of the release and "Supplemental Information and Notes to Non-GAAP Financial Measures" in the tables following the text of this release.

First-quarter 2011 sales grew 7.5% from the same period last year, or 7.3% excluding the effects of foreign currency translation. Sales increased 8.5% in Pharmaceutical Packaging Systems and 4.7% in Pharmaceutical Delivery Systems. The overall sales mix improved as a result of growing sales of high-value pharmaceutical packaging components and proprietary devices. Contract manufacturing revenues were flat due to scheduled price reductions that offset other gains, and sales of disposable medical device components declined. The Company's order backlog at the end of the quarter was over 11% higher than the comparable amounts at December 31 and March 31, 2010.

WST is just amazing...My largest holding too !!!

West to Host 2011 First Quarter Conference Call

West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Friday 22 April 2011
West Pharmaceutical Services, Inc. (NYSE:WST) announced today that it will release 2011 first quarter financial results before the market opens on Thursday, April 28, 2011 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial 866-713-8566 (U.S.) or 617-597-5325 (International). The passcode is 44873024

Sold this am at $45.62